Who are Foghorn Therapeutics Inc.'s main suppliers?

Foghorn Therapeutics Inc. (FHTX) key suppliers include: Eli Lilly and Company, Eli Lilly and Company. View the full supplier network at chainsifter.com/chain/FHTX.

Who are Foghorn Therapeutics Inc.'s major customers?

Foghorn Therapeutics Inc. (FHTX) key customers include: LILLY, Eli Lilly and Company, Eli Lilly and Company, EVERCORE-GROUP-LLC, Evercore Inc.. View the full customer network at chainsifter.com/chain/FHTX.

What sector is Foghorn Therapeutics Inc. in?

Foghorn Therapeutics Inc. (FHTX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Foghorn Therapeutics Inc. (FHTX): 10 Verified Supply Chain Relationships

2Suppliers

5Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Foghorn Therapeutics Inc. (FHTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

11Total relationships

4Distinct source URLs

7High confidence

0.818Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Foghorn Therapeutics Inc. Suppliers

Ticker	Name	Confidence	Evidence
LLY	Eli Lilly and Company	90%	Concurrent with the Lilly Collaboration Agreement, we also entered into a stock purchase agreement (the "Lilly SPA") with Lilly whereby we issued and sold Lilly 4,000,000 shares of our common stock, …
LLY	Eli Lilly and Company	90%	Reciprocal relationship from LLY graph: Reciprocal relationship from FHTX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from FHTX graph: Concurrent with the Lilly Collaborati…

Foghorn Therapeutics Inc. Customers

Ticker	Name	Confidence	Evidence
LILLY	LILLY	92%	Lilly is a leading oncology company with a track record of innovation and execution
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from FHTX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from FHTX graph: Reciprocal relationship from LLY grap…
LLY	Eli Lilly and Company	72%	e than 500,000 cancer patients. We take a small molecule modality agnostic approach to drugging 63 Table of Contents targets which includes protein degraders, allosteric enzymatic inhibitors, and tra…
EVERCORE-GROUP-LLC	EVERCORE-GROUP-LLC	62%	e than 500,000 cancer patients. We take a small molecule modality agnostic approach to drugging 63 Table of Contents targets which includes protein degraders, allosteric enzymatic inhibitors, and tra…
EVR	Evercore Inc.	62%	Reciprocal relationship from EVR graph: Reciprocal relationship from FHTX graph: e than 500,000 cancer patients. We take a small molecule modality agnostic approach to drugging 63 Table of Contents t…

Foghorn Therapeutics Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
FHTX-DEBT-9497	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2020-12-31.
FHTX-DEBT-9496	Warrants outstanding: 114000	90%	xbrl warrant detail from xbrl 2021-12-31.
FHTX-DEBT	Debt stack $42.0M	90%	Market cache reports total debt of $42.0M.

Foghorn Therapeutics Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Foghorn Therapeutics Inc..

Foghorn Therapeutics Inc. Ownership

Holder	Name	Confidence	Evidence
FHTX-OWNER-FLAGSHIP-PIONEERING-LLC	Flagship Pioneering, LLC	90%	13F overlay lists Flagship Pioneering, LLC as top holder; 105 tracked holders.

Foghorn Therapeutics Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ACIU	AC Immune SA	100.00	2
INCY	Incyte Corporation	100.00	2
ALEC	Alector, Inc.	100.00	2
BYSI	BeyondSpring Inc.	100.00	2
FDMT	4D Molecular Therapeutics, Inc.	100.00	2
IMNM	Immunome, Inc.	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
ACRS	Aclaris Therapeutics, Inc.	100.00	2
CRIS	Curis, Inc.	100.00	2
EVR	Evercore Inc.	100.00	1	['customer']
DSGN	Design Therapeutics, Inc.	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
NVO	Novo Nordisk A/S	100.00	2
AKTS	Aktis Oncology, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
IVA	Inventiva S.A.	100.00	2

Foghorn Therapeutics Inc. Supply Chain